Please login to the form below

Not currently logged in
Email:
Password:

Elan reveals new hires to board

Irish-headquartered Elan has appointed Jonas Frick and Giles Kerr as non-executive directors of the company.

Irish-headquartered Elan has appointed Jonas Frick and Giles Kerr as non-executive directors of the company.

Frick is the former CEO of Scandinavian Life Science Ventures (SLS Ventures), an investment company in the life science sector in Scandinavia.

Before joining SLS Ventures, Frick was the CEO and President of the publicly traded biotech company Medivir. He has also worked in senior executive positions in Pharmacia's international businesses in the CNS and Autoimmune areas across Italy, Sweden and Japan.

Kerr is currently director of finance with the University of Oxford and a fellow of Keble College. He is also director and chairman of the Audit Committee of Victrex and a director of Isis Innovation.

Prior to these roles, he was group finance director and CFO of Amersham, a UK-based medical diagnostics and life science company, whic was acquired by GE Healthcare in 2004.

Kyran McLaughlin, chairman of Elan, said, "We are delighted to welcome Jonas and Giles to our board. Their experience and enthusiasm will add greatly to the overall board and to the company. This represents another important step in developing the board's composition to achieve the appropriate mix of backgrounds and industry experience."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics